Trial Profile
A Phase I Study of TQ-B3525 on Tolerance and Pharmacokinetics
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2023
Price :
$35
*
At a glance
- Drugs TQ-B3525 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 12 Apr 2023 Planned End Date changed from 31 Dec 2019 to 1 Aug 2024.
- 02 May 2018 New trial record